StockTipsArenaBeta

BUY Lupin Limited — Dharmesh Kant, Cholamandalam Securities

BUYLupin Limited
Lupin share price target & all analyst calls

byDharmesh Kant, Cholamandalam SecuritiesHorizon: 1 year3 Jul 2026via CNBC Awaaz.

Entry₹2,473Inferred
Target₹2,900
Total upside +17.27% (call closed)
Stop loss₹2,470-0.12% risk
Exit₹2,4703 Jul 2026, 3:29 pm
Stop-loss hit-0.12%
Follow Dharmesh Kant for new callsGet alertsWatch LUPIN for new buy/sell callsGet alertsSee 12 active Long-term calls on LUPINSee 214 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 3 Jul 2026
21 supporting1 neutral0 opposing
Supports the BUY call (21)

Lupin Ltd has received an Establishment Inspection Report (EIR) from the U.S. FDA for its Somerset facility, classifying it with Voluntary Action Indicated (VAI).

BSE · Company Update·1 Jul · yesterday

(opens in new tab)

Lupin Ltd provided updates on the acquisition of minority shareholding in its subsidiary, Multicare Pharmaceuticals Philippines, Inc. (MPPI), and a share buyback by MPPI.

BSE · Company Update·1 Jul · yesterday

(opens in new tab)

Lupin announced that the European Medicines Agency (EMA) has approved a change to the marketing authorization for NaMuscla, including new dosage strengths and expanded pediatric indications for non-dy

BSE · Company Update·1 Jul · yesterday

(opens in new tab)

Lupin Limited received tentative approval from the U.S. FDA for Enzalutamide Tablets on June 26, 2026. This is a step towards potential market approval.

NSE · Press Release·26 Jun · 1w ago

(opens in new tab)

4 other SEBI-registered advisors have active long-term BUY calls on this stock

Advisor consensus · same horizon·19 Jun · 2w ago

Neutral / worth noting (1)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Lupin

All analyst calls on Lupin

More from Dharmesh Kant, Cholamandalam Securities

Every call and its outcome